Phase 3 ATOMIC trial Updates: Atezolizumab plus FOLFOX for Stage III dMMR Colon Cancer

oncodaily - Patients with stage III colon cancer are typically treated with surgical resection followed by adjuvant chemotherapy with a fluoropyrimidine-plus-oxaliplatin regimen. However, approximately 30% of patients with stage III disease experience […]

AI Summary: Phase 3 ATOMIC updates show that adding atezolizumab to FOLFOX/mFOLFOX6 improves disease‑free survival in patients with Stage III dMMR colon cancer, with a substantial reduction in recurrence risk reported. The results suggest immunotherapy may become integral to adjuvant treatment for this biomarker‑defined subgroup.


ATOMIC breakthrough: atezolizumab reduces recurrence in dMMR colon patients

Microsatellite Instability (MSI)-The Biomarker That Changed Oncology Practice

3 months / oncodaily

Phase 3 ATOMIC trial Updates: Atezolizumab plus FOLFOX for Stage III dMMR Colon Cancer

3 months / oncodaily

Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer

3 months / esmo


From the wards: MSI-H immunotherapy expands beyond colon

Blood-based biomarker could help stratify cancer risk in Lynch Syndrome

3 months / medicalxpress

KEYNOTE-158 Trial: Pembrolizumab Monotherapy in MSI-H/dMMR Recurrent Gliomas:

3 months / oncodaily

Mohammad Jad Moussa: Immune Checkpoint Inhibitors in dMMR/MSI-H Advanced Upper Tract Urothelial Carcinoma

3 months / oncodaily


On the frontline: colorectal biomarkers and therapy innovations

Cathy Eng: Colorectal Cancer Screening Emphasized as Year-Round Priority

3 months / oncodaily

Scientists target key protein duo driving colon, liver cancer

3 months / medicalxpress

Fabio Carbone: Meta-analysis on Blood-based ctDNA for Colorectal Cancer Screening

3 months / oncodaily

Sepideh Gholami: Excited To Share Our Recent Work On CXCR4 In Metastatic Colorectal Cancer

3 months / oncodaily

Impact of chemotherapy exposure on tumor mutation burden in advanced colorectal cancer

3 months / nature

Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study

3 months / nature


Other headlines: cancer research news outside ATOMIC focus

Study inspired by Sarah Harding identifies early breast cancer in Manchester mum

3 months / cancerresearchuk / Nisharnthi Duggan


All Other Stories

Nicholas Hornstein: Treatment De-Escalation and Holidays in BRAF+ mCRC Spark Discussion

3 months / oncodaily

Immune Checkpoint Inhibitors Show Durable Responses in dMMR/MSI-H UTUC

3 months / oncodaily

Innocent H. Peter Uggh: Global Colon Cancer Association Opens Speaker Applications for 2026 Congress

3 months / oncodaily




Related Stories

EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days

Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 6 wks

Common asthma drug may overcome immunotherapy resistance in cancers / 7 wks

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 7 wks

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Alzheimer's disease, Oncology, Novo Nordisk, Digital Health and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.